---
title: "UK Regulator OKs Telix Pharmaceuticals' Imaging Agent for Prostate Cancer Detection"
date: "2025-02-13 01:15:27"
summary: "The UK Medicines and Healthcare products Regulatory Agency granted Telix Pharmaceuticals (UK) marketing authorization for its gozetotide, an agent used in PET scans for the detection of prostate cancer in adults. The British regulator said Wednesday gozetotide met the appropriate regulatory safety, quality and effectiveness standards. The agency also noted..."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

The UK Medicines and Healthcare products Regulatory Agency granted Telix Pharmaceuticals (UK) marketing authorization for its gozetotide, an agent used in PET scans for the detection of prostate cancer in adults.

The British regulator said Wednesday gozetotide met the appropriate regulatory safety, quality and effectiveness standards.

The agency also noted potential side effects caused by gozetotide, including the increased blood level of a digestive enzyme, constipation, weakness and a warm sensation on the injection site.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250212:G2466974:0/)
